From Payload to Patient: Managing Toxicities of Antibody-Drug Conjugates Directed at HER2 and TROP2

Program Description

Antibody-drug conjugates (ADCs) are a fast-growing class of cancer therapies, with approvals doubling in the past 4 years and expanding into new indications as well as frontline and combination treatment. However, the rapid introduction of novel ADCs has outpaced the development of standardized toxicity management protocols, leading to gaps in care due to variable toxicity profiles and inconsistent pre-treatment processes. While ADCs are engineered for targeted delivery to minimize toxicity, treatment-related adverse events can still occur and may vary significantly between patients due to factors like baseline organ function, comorbidities, pharmacogenomics, body composition, and prior therapies. Toxicities from ADCs directed at HER2 and TROP2 range from immediate to delayed-onset and can sometimes be life-threatening, requiring timely, proactive management strategies. Pharmacists play a key role in managing ADC-related toxicities, from ocular care and interstitial lung disease management to gastrointestinal and chemotherapy-induced nausea and vomiting, and can have key roles in implementing recommended prophylactic protocols, overseeing appropriate monitoring, and providing effective counseling. This educational program aims to equip oncology pharmacists with practical approaches to manage the unique toxicities of HER2-directed and TROP2-directed ADCs. Faculty will engage in a patient case discussion designed to explore key factors in treatment selection and medication management. By learning prophylactic strategies, early identification, and comprehensive management of these toxicities, pharmacists can enhance patient safety, treatment tolerability, and long-term outcomes.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 5, 2025
Expiration date: December 5, 2026
Learner level: Foundational, Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Examine the unique toxicity profiles of antibody-drug conjugates (ADCs) directed at HER2 and TROP2, considering factors such as tumor subtype, previous therapies, and patient-specific characteristics
2. Factor agent- and patient-specific monitoring parameters and prophylactic strategies into streamlined workflows to mitigate toxicities of HER2-directed and TROP2-directed ADCs and support health-related quality of life
3. Analyze how pharmacists can work within health care teams to use both medication-based and nonpharmacologic approaches to manage common and serious adverse effects of ADCs directed at HER2 and TROP2

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-397-H05-P. The activity is available for CE credit through December 5, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Sophia Gilardone, PharmD, BCOP

Medical Writing and Editorial Support

Bruce I. Gaynes, OD, PharmD

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms